Search
Close Search

Stay on Track

To reduce the risk of undetected bladder cancer recurrence it's important you keep up with all your scheduled surveillance check-ups.

Cxbladder Monitor is a genomic urine test that can help ease the burden of invasive testing, safely reducing the frequency of cystoscopy required in patients being monitored for recurrent non-muscle invasive urothelial bladder cancer.

  • Accurate: Cxbladder is an advanced genomic test that delivers exceptional performance and meaningful results.
  • Clinically proven: The Cxbladder evidence portfolio includes more than 20 peer reviewed publications. Cxbladder has been used by over 5,000 urologists in more than 100,000 patients, and is accessible to 75% of the New Zealand population via public healthcare.
  • Non-invasive and easy-to-use: Cxbladder's non-invasive urine sampling system is quick and easy to use, taking only minutes.
  • In-home sampling: To streamline care we are now offering an in-home sampling service for comfort and convenience.
  • Quick: Upon receiving a urine sample, our certified laboratory will provide actionable results in 5 business days.

Bladder Cancer Patients have Unique Monitoring Needs

Patients that have been treated for non-invasive bladder cancer have unique monitoring needs to protect against the threat of recurrence. After assessing a patient’s risk profile, doctors will recommend a regular ongoing schedule of cystoscopies to examine the inside of the bladder and urethra.

If You’re Being Monitored for Bladder Cancer Recurrence, Ask Your Doctor About Cxbladder 

Cxbladder Monitor is a non-invasive alternative that can reduce the burden of cystoscopy in those being monitored for recurrent non-muscle invasive bladder cancer.

  • In suitable cases, a negative Cxbladder Monitor test result can safely postpone the need to undergo an invasive procedure .1
  • When no recurrence has been detected after several years,  a Cxbladder Monitor test may provide an alternative to cystoscopy after consulting with your physician.​

Contact us to learn more

1 Li K, Chu C, Patel M, Meng M, Morgan T, Porten S. Cxbladder Monitor testing to reduce cystoscopy frequency in patients with bladder cancer. Urol Oncol. 2023 Mar 1;S1078-1439(23)00009-1. doi: 10.1016/j.urolonc.2023.01.009  

Proven Performance

With proven performance in more than 20 peer-reviewed publications, Cxbladder is used by over 5,000 urologists in more than 100,000 patients.

Multiple clinical trials have shown Cxbladder Monitor to be a highly accurate test for ruling out tumors. A study with data from over 1,100 US patient samples found that Cxbladder Monitor significantly outperforms current FDA-approved urine-based monitoring tests, including cytology and UroVysion FISH2. 

It's important to note that no test or procedure is 100% accurate, including cystoscopy. Cxbladder Monitor has been clinically validated with a sensitivity of 93% and a negative predictive Value (NPV) of 97%.

Browse Our Clinical Publications

2 Lotan Y, OʼSullivan P, Raman JD, Shariat SF, Kavalieris L, Frampton C, et al. Clinical comparison of non-invasive urine tests for ruling out recurrent urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations. Elsevier; 2017;1–8.  

Non-Invasive and Easy-to-Use

Cxbladder’s urine sample collection system is non-invasive and easy-to-use, taking only minutes. Watch our instructions for use video to learn more. 

Stay on Track with Cxbladder

Non-invasive genomic tests are now playing an important role in cancer care and patients around the world are experiencing the benefits. If you’re concerned about recurrent non-muscle invasive bladder cancer, Cxbladder can provide reliable answers while helping to safely reduce the burden of invasive testing.

Don’t derail your care. Stay on track with Cxbladder.

Call us at 0800-CXBLADR (0800-2925-237).

Contact us to learn more

Last Updated: 01 May 2024 11:07 am